$REGN mention timeline

Regeneron Pharmaceuticals. Every tracked FinTwit mention of $REGN, newest first. 22 mentions since the first on Jun 30, 2025. See the price chart.

May 2026 · 2 mentions

May 18
Adam Feuerstein ✡️ — @CloisterRes B/c $REGN promised it would work.↗
May 16
Adam Feuerstein ✡️ — $REGN acting like a penny stock biotech shitco. Shamefull. Lag3 fail. https://t.co/AUdzIsVmgW↗

Apr 23
Adam Feuerstein ✡️ — $REGN wins FDA approval for its gene therapy to treat a very rare genetic form of hearing loss. The company is giving away the therapy for free. OTOF-related hearing loss affects…↗

Mar 16
Jacob Plieth — Who knew $REGN was developing an anti-GPRC5D T-cell engager? https://t.co/jyL1PAS0y5 $JNJ $PFE $BMY↗

Dec 19
Adam Feuerstein ✡️ — Important new FDA reporting from @LizzyLaw_ @statnews FDA voucher program has become vehicle for political interference in drug review decisions, staffers say A new program int…↗
Dec 9
Jacob Plieth — If you enjoyed #ASH25 you can catch up on all @ApexOnco coverage, including previews, here -> https://t.co/XIQrEeKMwY $TERN $JNJ $LLY $CGEM $ONC $NRIX $PFE $REGN $KURA↗
Dec 8
Adam Feuerstein ✡️ — Kymera $KYMR drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial https://t.co/W3m3dtydJR via @JonathanWosen $SNY $REGN↗

Oct 24
Adam Feuerstein ✡️ — How the first nine drug companies won priority review vouchers from Marty Makary’s FDA https://t.co/6r3UlcN8Wn via @LizzyLaw_ $DISC $RVMD $REGN $ACHV↗
Oct 16
Adam Feuerstein ✡️ — Also on the voucher list: $REGN DB-OTO gene therapy for deafness.↗
Oct 13
Adam Feuerstein ✡️ — FDA declares Novo Nordisk $NVO (Catalent) plant, key to drug manufacturing for some biotechs, out of compliance. Impacting $SRRK and $REGN today. https://t.co/LLlei1xM7X via @el…↗

Sep 24
Jacob Plieth — CRLs for $REGN Eylea & odronextamab, & $SRRK apitegromab, so it must be time for a party! https://t.co/S78cFYGFkh↗
Sep 4
Jacob Plieth — FDA appears not to have published these recent CRLs (or have I missed them??): Linvoseltamab $REGN Datroway $AZN $DSNKY Talzenna $PFE Columvi $RHHBY↗
Sep 4
Jacob Plieth — Quite a few (redacted) oncology CRLs released then: $REGN odronextamab x3 SC Rybrevant $JNJ $REPL $ATRA Patri-dxd $MRK $DSNKY Camrelizumab + rivoceranib x2↗

Aug 21
Adam Feuerstein ✡️ — U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, FDA finds Plant, once owned by $CTLT and now owned by Novo Nordisk $NVO, is widely u…↗
Aug 19
Adam Feuerstein ✡️ — $ALNY surpassed $REGN in market value today. https://t.co/hckkdLHErO↗
Aug 7
Jacob Plieth — As if $REGN TCE division needed any more bad news, $GMAB Epcore FL-1 just read out positively, about 3 years ahead of schedule as far as I can tell.↗
Aug 1
Adam Feuerstein ✡️ — $REGN regulatory update: Expects Eylea HD pre-filled syringe and RVO approval delays (August PDUFAs) due to FDA general site inspection issues at Catalent's Indiana manufacturing…

Jul 31
Jacob Plieth — So any word from $REGN? Odronextamab Pdufa date (now only for follicular) was yesterday.↗
Jul 2
Jacob Plieth — @BiotechObserver Patient deaths, manufacturing cockups, 2 CRLs, one indication dropped. Right... $REGN↗
Jul 2
Jacob Plieth — $REGN Lynozyfic approved (8 days before Pdufa date)... odronextamab next?↗